Large-Scale Multicenter Prospective Registry Study of Ripretinib in Advanced GIST: A Real-World Study from China

    June 2023 in “ Advances in therapy
    Xinhua Zhang, Peng Zhang, Haibo Qiu, Yong Fang, Heli Liu, Yongjian Zhou, Hao Xu, Jiren Yu, Jun Zhang, Ming Wang, Lin Shen, Jian Li
    Image
    Studysummary In a real-world registry study, ripretinib showed effectiveness with a median progression-free survival of 7.70 months and a tolerable safety profile in Chinese patients using it as a fourth-line treatment for advanced GIST, particularly benefiting those with non-gastric tumors.
    Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer
    Discuss this study in the Community →

    Research cited in this study

    3 / 3 results